Tags

Type your tag names separated by a space and hit enter

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus.
J Clin Med. 2020 Jun 01; 9(6)JC

Abstract

Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power.

Authors+Show Affiliations

Department of Diabetes, Endocrinology and Metabolism, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan. Department of Cardiology, Nakagami Hospital, 610 Noborikawa, Okinawa 904-2195, Japan.Department of Cardiology, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 901-0243, Japan.Department of Diabetes and Life-Style Related Disease Center, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 901-0243, Japan.Department of Cardiology, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 901-0243, Japan.Department of Diabetes, Endocrinology and Metabolism, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32492927

Citation

Yamaguchi, Satoshi, et al. "Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients With or Without Type 2 Diabetes Mellitus." Journal of Clinical Medicine, vol. 9, no. 6, 2020.
Yamaguchi S, Oba K, Higa M, et al. Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. J Clin Med. 2020;9(6).
Yamaguchi, S., Oba, K., Higa, M., Arasaki, O., & Shimabukuro, M. (2020). Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 9(6). https://doi.org/10.3390/jcm9061675
Yamaguchi S, et al. Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients With or Without Type 2 Diabetes Mellitus. J Clin Med. 2020 Jun 1;9(6) PubMed PMID: 32492927.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. AU - Yamaguchi,Satoshi, AU - Oba,Kageyuki, AU - Higa,Moritake, AU - Arasaki,Osamu, AU - Shimabukuro,Michio, Y1 - 2020/06/01/ PY - 2020/05/03/received PY - 2020/05/28/revised PY - 2020/05/29/accepted PY - 2020/6/5/entrez PY - 2020/6/5/pubmed PY - 2020/6/5/medline KW - age KW - ezetimibe KW - low-density lipoprotein cholesterol JF - Journal of clinical medicine JO - J Clin Med VL - 9 IS - 6 N2 - Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power. SN - 2077-0383 UR - https://www.unboundmedicine.com/medline/citation/32492927/Age-Dependent_Efficacy_of_Ezetimibe_for_Low-Density_Lipoprotein_Cholesterol_Reduction_in_Japanese_Patients_with_or_without_Type_2_Diabetes_Mellitus L2 - https://www.mdpi.com/resolver?pii=jcm9061675 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.